The Mitochondria in Diabetic Heart Failure: From Pathogenesis to Therapeutic Promise
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
SIGNIFICANCE: Diabetes is an important risk factor for the development of heart failure (HF). Given the increasing prevalence of diabetes in the population, strategies are needed to reduce the burden of HF in these patients. RECENT ADVANCES: Diabetes is associated with several pathologic findings in the heart including dysregulated metabolism, lipid accumulation, oxidative stress, and inflammation. Emerging evidence suggests that mitochondrial dysfunction may be a central mediator of these pathologic responses. The development of therapeutic approaches targeting mitochondrial biology holds promise for the management of HF in diabetic patients. CRITICAL ISSUES: Despite significant data implicating mitochondrial pathology in diabetic cardiomyopathy, the optimal pharmacologic approach to improve mitochondrial function remains undefined. FUTURE DIRECTIONS: Detailed mechanistic studies coupled with more robust clinical phenotyping will be necessary to develop novel approaches to improve cardiac function in diabetes. Moreover, understanding the interplay between diabetes and other cardiac stressors (hypertension, ischemia, and valvular disease) will be of the utmost importance for clinical translation of scientific discoveries made in this field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 1×
“Of interest, intensive blood glucose control does not reduce the incidence of HF in diabetic patients (28, 77).”
The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance
Vandanmagsar, B., Youm, Y.-H., Ravussin, A., Galgani, J. E., Stadler, K., Mynatt, R. L., Ravussin, E., Stephens, J. M., & Dixit, V. D. (2011) · Nature Medicine · doi:10.1038/nm.2279 · Cited by 2,655
Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis
Shimada, K., Crother, T. R., Karlin, J., Dagvadorj, J., Chiba, N., Chen, S., Ramanujan, V. K., Wolf, A. J., Vergnes, L., Ojcius, D. M., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.01.009 · Cited by 2,282
Triglyceride accumulation protects against fatty acid-induced lipotoxicity
Listenberger, L. L., Han, X., Lewis, S. E., Cases, S., Farese, R. V., Ory, D. S., & Schaffer, J. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0630588100 · Cited by 2,075
Koves, T. R., Ussher, J. R., Noland, R. C., Slentz, D., Mosedale, M., Ilkayeva, O., Bain, J., Stevens, R., Dyck, J. R. B., Newgard, C. B., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.013 · Cited by 1,990
Vitamin E Supplementation and Cardiovascular Events in High-Risk Patients
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420302 · Cited by 1,957
PGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditure
Cantó, C., & Auwerx, J. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328328d0a4 · Cited by 1,624
(2005) · JAMA · doi:10.1001/jama.293.11.1338 · Cited by 1,209 · cited 1×
“However, when investigated in humans, these antioxidants either alone or in combination have not shown consistent beneficial effects on serum metabolic parameters or the incidence of cardiovascular disease (65, 108).”
Molecular mechanisms of diabetic cardiomyopathy
Bugger, H., & Abel, E. D. (2014) · Diabetologia · doi:10.1007/s00125-014-3171-6 · Cited by 903
Fullerton, M. D., Galic, S., Marcinko, K., Sikkema, S., Pulinilkunnil, T., Chen, Z.-P., O'Neill, H. M., Ford, R. J., Palanivel, R., O'Brien, M., et al. (2013) · Nature Medicine · doi:10.1038/nm.3372 · Cited by 893
Myocardial Cell Death in Human Diabetes
Frustaci, A., Kajstura, J., Chimenti, C., Jakoniuk, I., Leri, A., Maseri, A., Nadal-Ginard, B., & Anversa, P. (2000) · Circulation Research · doi:10.1161/01.res.87.12.1123 · Cited by 796 · cited 1×
“Irrespective of the mechanism, there is strong evidence demonstrating that increased oxidative stress is a common feature observed in cardiac tissue from humans or animals with diabetic CM (38, 104).”
Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart
Sharma, S., Adrogue, J. V., Golfman, L., Uray, I., Lemm, J., Youker, K., Noon, G. P., Frazier, O. H., & Taegtmeyer, H. (2004) · The FASEB Journal · doi:10.1096/fj.04-2263com · Cited by 790 · cited 1×
“Cardiac inflammation and leukocyte recruitment is increased in both animal models and humans with diabetes and HF (48, 85, 88, 102, 103).”
The inflammasome: an integrated view
Gross, O., Thomas, C. J., Guarda, G., & Tschopp, J. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01046.x · Cited by 778 · cited 1×
“It is now established that mitochondrial damage, particularly in the context of toll-like receptor activation with release of mitochondrial DNA and/or ROS, can activate the NLRP3 inflammasome, leading to the cleavage and release of IL-1b and IL-18 through a caspase 1-dependent mechanism (42, 90, 109).”
Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury
Adlam, V. J., Harrison, J. C., Porteous, C. M., James, A. M., Smith, R. A. J., Murphy, M. P., & Sammut, I. A. (2005) · The FASEB Journal · doi:10.1096/fj.05-3718com · Cited by 618 · cited 1×
“The only cardiac data with this agent come from a rat model of ischemiareperfusion injury where MitoQ was shown to reduce myocyte injury and improve contractile function (2).”
Mitochondrial Energetics in the Heart in Obesity-Related Diabetes
Boudina, S., Sena, S., Theobald, H., Sheng, X., Wright, J. J., Hu, X. X., Aziz, S., Johnson, J. I., Bugger, H., Zaha, V. G., et al. (2007) · Diabetes · doi:10.2337/db07-0481 · Cited by 586
Finck, B. N., Han, X., Courtois, M., Aimond, F., Nerbonne, J. M., Kovacs, A., Gross, R. W., & Kelly, D. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0336724100 · Cited by 501
Anderson, E. J., Kypson, A. P., Rodriguez, E., Anderson, C. A., Lehr, E. J., & Neufer, P. D. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.031 · Cited by 440
Muoio, D. M., Noland, R. C., Kovalik, J.-P., Seiler, S. E., Davies, M. N., DeBalsi, K. L., Ilkayeva, O. R., Stevens, R. D., Kheterpal, I., Zhang, J., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.005 · Cited by 372
Lipid-Induced Mitochondrial Stress and Insulin Action in Muscle
Muoio, D. M., & Neufer, P. D. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.010 · Cited by 343 · cited 2×
“The FA-carnitines are subsequently converted back to FA-CoAs by CPT2 present on the inner mitochondrial membrane.”
Belke, D. D., Betuing, S., Tuttle, M. J., Graveleau, C., Young, M. E., Pham, M., Zhang, D., Cooksey, R. C., McClain, D. A., Litwin, S. E., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0213946 · Cited by 330
Montaigne, D., Marechal, X., Coisne, A., Debry, N., Modine, T., Fayad, G., Potelle, C., El Arid, J.-M., Mouton, S., Sebti, Y., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.008476 · Cited by 322
Diabetes in heart failure: prevalence and impact on outcome in the population
From, A. M., Leibson, C. L., Bursi, F., Redfield, M. M., Weston, S. A., Jacobsen, S. J., Rodeheffer, R. J., & Roger, V. L. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.05.024 · Cited by 295 · cited 2×
“Diabetes is also extremely common in patients who have HF with reduced EF (HFrEF), with a prevalence approaching 40% in many HF registries and clinical trials.”
CD36 Deficiency Rescues Lipotoxic Cardiomyopathy
Yang, J., Sambandam, N., Han, X., Gross, R. W., Courtois, M., Kovacs, A., Febbraio, M., Finck, B. N., & Kelly, D. P. (2007) · Circulation Research · doi:10.1161/01.res.0000264104.25265.b6 · Cited by 246
Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond
Daffu, G., Del Pozo, C., O'Shea, K., Ananthakrishnan, R., Ramasamy, R., & Schmidt, A. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141019891 · Cited by 222 · cited 1×
“For example, it would be expected that STZ-treated, hyperglycemic mice would have increased total oxidative stress with a greater contribution from nonmitochondrial ROS pathways ( i.e ., RAGE/NADPH oxidase) (21).”
Cardiovascular Phenotype in HFpEF Patients With or Without Diabetes
Lindman, B. R., Dávila-Román, V. G., Mann, D. L., McNulty, S., Semigran, M. J., Lewis, G. D., de las Fuentes, L., Joseph, S. M., Vader, J., Hernandez, A. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.05.030 · Cited by 209 · cited 1×
“Along these lines, the influence of diabetes on HFpEF was recently reported in a subset of patients from the RELAX trial (61).”
Prevention of diabetic nephropathy in Ins2+/−AkitaJ mice by the mitochondria-targeted therapy MitoQ
Chacko, B. K., Reily, C., Srivastava, A., Johnson, M. S., Ye, Y., Ulasova, E., Agarwal, A., Zinn, K. R., Murphy, M. P., Kalyanaraman, B., et al. (2010) · Biochemical Journal · doi:10.1042/bj20100308 · Cited by 204
Mitochondrial Uncoupling: A Key Contributor to Reduced Cardiac Efficiency in Diabetes
Boudina, S., & Abel, E. D. (2006) · Physiology · doi:10.1152/physiol.00008.2006 · Cited by 199 · cited 1×
“In support of UCPs contributing to the metabolic derangements in diabetes, mitochondria isolated from diabetic mouse hearts have elevated rates of oxygen consumption, increased un-coupled respiration, and reduced efficiency (13).”
Feedback interactions in the control of citric acid cycle activity in rat heart mitochondria
LaNoue, K. F., Bryla, J., & Williamson, J. R. (1972) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)45660-3 · Cited by 181
Son, N.-H., Yu, S., Tuinei, J., Arai, K., Hamai, H., Homma, S., Shulman, G. I., Abel, E. D., & Goldberg, I. J. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40905 · Cited by 159
Abdul-Ghani, M. A., Muller, F. L., Liu, Y., Chavez, A. O., Balas, B., Zuo, P., Chang, Z., Tripathy, D., Jani, R., Molina-Carrion, M., et al. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90287.2008 · Cited by 140 · cited 9×
“How does this balance become disrupted to produce a net increase in oxidative stress during diabetes? One possible mechanism is related to the ability of LCFA and their partially oxidized derivatives to directly impair the function of the ETC (1).”
InfluentialAguilar, D., Deswal, A., Ramasubbu, K., Mann, D. L., & Bozkurt, B. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.09.041 · Cited by 96 · cited 1×
“This is particularly true in patients with other associated conditions such as hypertension (HTN), ischemic heart disease, or aortic stenosis where the presence of diabetes accentuates the cardiac hypertrophic response and worsens LV function (3, 10, 41, 44, 60).”
Lindman, B. R., Arnold, S. V., Madrazo, J. A., Zajarias, A., Johnson, S. N., Pérez, J. E., & Mann, D. L. (2011) · Circulation: Heart Failure · doi:10.1161/circheartfailure.110.960039 · Cited by 68 · cited 1×
“This is particularly true in patients with other associated conditions such as hypertension (HTN), ischemic heart disease, or aortic stenosis where the presence of diabetes accentuates the cardiac hypertrophic response and worsens LV function (3, 10, 41, 44, 60).”
Cited by
Mitochondrial dysfunction and oxidative stress in heart disease
Peoples, J. N., Saraf, A., Ghazal, N., Pham, T. T., & Kwong, J. Q. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0355-7 · Cited by 950
Mitochondrial ROS Formation in the Pathogenesis of Diabetic Cardiomyopathy
Kaludercic, N., & Di Lisa, F. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00012 · Cited by 263
Hu, L., Ding, M., Tang, D., Gao, E., Li, C., Wang, K., Qi, B., Qiu, J., Zhao, H., Chang, P., et al. (2019) · Theranostics · doi:10.7150/thno.33684 · Cited by 254
Mitochondrial Function and Dysfunction in Dilated Cardiomyopathy
Ramaccini, D., Montoya-Uribe, V., Aan, F. J., Modesti, L., Potes, Y., Wieckowski, M. R., Krga, I., Glibetić, M., Pinton, P., Giorgi, C., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.624216 · Cited by 136
“A detailed review by Schilling (2015) discusses the hypothesis that diabetes promotes mitochondrial dynamic dysregulation, which is a trigger in the development of diabetic-induced cardiomyopathy progression and heart failure.”
BackgroundMitochondrial health, the epigenome and healthspan
Aon, M. A., Cortassa, S., Juhaszova, M., & Sollott, S. J. (2016) · Clinical Science · doi:10.1042/cs20160002 · Cited by 66
Metadata
- Authors
- Schilling, J. D.
- Venue
- Antioxidants & Redox Signaling
- Publisher
- SAGE Publications
- Published
- 2015-06-10
- Volume
- 22
- Issue
- 17
- Pages
- 1515-1526
- ISSN
- 1523-0864 (ISSN-L)
- 1557-7716
- OpenAlex
- W2033875805
- Cited by
- 87
- References
- 33
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.